A scalable CAR-T cell manufacturing workflow producing 100+ doses per batch

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

A scalable CAR-T cell manufacturing workflow producing 100+ doses per batch

Live30 webinars pack the latest innovations and applications into a data-rich 30-minute session.

This webinar presents data from a collaborative study between University College London, Sartorius, and Repligen, demonstrating a scalable allogeneic anti-CD19 CAR-T manufacturing workflow. Attendees will gain practical, evidence-based strategies for scaling up CAR-T bioprocesses in single-use stirred-tank bioreactors from early development to clinical manufacturing, while maintaining product quality and reducing process risk.

The session includes a detailed case study covering cell growth, metabolism, phenotype, and in vitro cytotoxicity data, demonstrating 125-fold cell expansion and production of 100+ CAR-T doses per batch with high viability and a central memory-enriched, low-exhaustion phenotype.

Attend this webinar to:

Review data from a 250 mL to 2 L scale-up of an anti-CD19 CAR-T workflow in single-use stirred-tank bioreactors using a serum-free medium
Understand how alternating tangential flow (ATF) perfusion can maximize CAR-T cell yields and support robust, high-density cultures
Evaluate a validated 250 mL scale-down model to streamline process development and reduce risk ahead of clinical-scale manufacturing
Gain practical guidance on implementing bio-capacitance for real-time, online monitoring of CAR-T cell concentrations
Learn how automated harvesting and buffer exchange influence critical quality attributes

Register now to access data-driven strategies for scaling CAR-T manufacturing in stirred-tank bioreactors and building robust, clinical-ready upstream and downstream workflows.

Pierre Springuel, PhD

Marketeer, Cell and Gene Therapy at Sartorius

Pierre holds a PhD in Biochemical Engineering from the University College London, with research focused on CAR‑T process intensification and scale‑up in stirred‑tank bioreactors.

Rukmini Ladi

Segment Technology Manager, Cell Therapy at Sartorius

Rukmini is a Bioprocess Development Engineer with several years of experience in immune and stem cell therapies. As a Segment Technology Manager at Sartorius, she supports cell therapy developers with process design and optimization, focusing on scalable and efficient manufacturing. She also leads collaborations with industry and academic partners to advance cell therapy solutions.

In 27 Days

You have registered for this webinar